厄达替尼中国上市了吗？

It is a multi-target tyrosine kinase inhibitor, targeting FGFR1-4, RET, CSF1R, PDGFRA/B, FLT4, KIT and VEGFR2. Hyperphosphatemia caused by erdafitinib results from its sustained inhibition of the FGFR signaling pathway. New drug for the treatment of urothelial cancer in adults.

On April 12, 2019, the FDA announced accelerated approval of Erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial cancer whose disease has progressed despite platinum-based chemotherapy. The successful launch of Erdafitinib has undoubtedly brought new treatment options and opportunities to many patients. Is Erdafitinib launched in China?

At present, erdafitinib has not yet been launched in mainland China. For more drug-related information about erdafitinib, patients are advised to consult the customer service of Medical Companion Travel for detailed information.

The starting dose is 8 mg once daily, taken orally on an empty stomach or with food. For patients whose serum phosphorus levels fall below the target value of 5.5 mg/dL between days 14 and 21, the dose is increased to 9 mg once daily until disease progression or intolerance. The peak plasma concentration is reached 2.5 hours after taking the drug, with an average half-life of 59 hours. It reaches steady state after two weeks, with Cmax of 1399ng/mL, and the accumulation factor of plasma concentration is 4. The plasma protein binding rate is 99.8%, the apparent distribution volume is 29 liters, and the apparent clearance rate is 0.362 liters per hour. When erdafitinib is taken orally with a high-fat meal, there is no clinically meaningful effect on plasma concentrations. No dose adjustment of erdafitinib is required based on the patient's gender, age, weight, mild to moderate renal impairment, and mild hepatic impairment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: